All In Biotech

Drug Trial Radar · NCT06993844

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

A Phase 1/2, Open-label, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-mutant-selective PI3Kα Inhibitor, as Monotherapy and in Combination With Other Anticancer Therapies in Participants With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

233

Planned (sponsor's estimate)

Start

Jun 10, 2025

Primary completion

Jun 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Ensem TherapeuticsIndustry
Sponsor type
Industry
First posted
May 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors

Conditions

  • Advanced Solid Tumors
  • Advanced Breast Cancer

Interventions

  • ETX-636 dose escalationDrug

    ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet that will be taken once per day in 28-day cycles, to evaluate escalating dose levels.

  • ETX-636 dose escalation in combination with fulvestrantDrug

    ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet. ETX-636 will be taken in combination with fulvestrant in 28-day cycles, to evaluate escalating dose levels. EXT-636 is an oral tablet that will be taken once per day. Fulvestrant will be administered as an injection 2 weeks apart in the first 28 days, followed by monthly injections.

  • ETX-636 dose expansion in combination with fulvestrantDrug

    ETX-636 is a pan-mutant-selective PI3Kα Inhibitor and degrader in the form of an oral tablet. ETX-636 will be taken in combination with fulvestrant in 28-day cycles, to expand selected dose levels. EXT-636 is an oral tablet that will be taken once per day. Fulvestrant will be administered as an injection 2 weeks apart in the first 28 days, followed by monthly injections.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate Safety and Tolerability of ETX-636 monotherapy in Part A and ETX-636 plus fulvestrant combination therapy in Part BTime frame: First 28 days of treatment
  2. Evaluate Safety and Tolerability of ETX-636 monotherapy in Part A and ETX-636 plus fulvestrant combination therapy in Part BTime frame: Average of 6 months
  3. Select the Recommended Phase 2 Dose(s) (RP2D) in Part B to be further explored in Part C (combination therapy expansion)Time frame: Average of 6 months
  4. Evaluate efficacy of ETX-636 plus fulvestrant combination therapy at the RP2D(s) in Part CTime frame: Average of 6 months

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California · Recruiting

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California · Recruiting

  • Yale University, Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Carolina BioOncology Institute

    Huntersville, North Carolina · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • START

    San Antonio, Texas · Recruiting

  • NEXT

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Beijing Luhe Hospital,Capital Medical University

    Beijing, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, China · Recruiting

  • Shandong Cancer Hospital&Institute

    Shandong, China · Recruiting

  • Fudan University Shanghai Cancer Hospital

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.